Takeda Pharmaceutical Co. Ltd. has entered into an agreement with Janssen Pharmaceutical K.K. to co-promote Velcade (bortezomib) for Injection in Japan. Janssen Pharma launched Velcade in Japan in 2006 for the treatment of relapsed multiple myeloma. Velcade is currently approved in more than 90 countries and in 2009 achieved global sales of $1 billion. The co-promotion is expected to begin in 2Q10. Takeda will receive a percentage of sales as a co-promotion fee. Other financial terms of the a...